Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

Takeshi Tomoda, Kazuhiro Nouso, Koji Miyahara, Sayo Kobayashi, Hideaki Kunugasa, Junki Toyosawa, Hiroaki Hagihara, Kenji Kuwaki, Hideki Ohnishi, Shinichiro Nakamura, Fusao Ikeda, Yasuhiro Miyake, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aim: Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. Methods: Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. Results: Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P=0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio=2.41, 95% confidence interval=1.16-5.00, P=0.02). Conclusions: Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.

Original languageEnglish
Pages (from-to)1391-1396
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume28
Issue number8
DOIs
Publication statusPublished - 2013

Fingerprint

Follistatin
Hepatocellular Carcinoma
Serum
Chronic Hepatitis
Portal Vein
Liver Cirrhosis
Neoplasms
Healthy Volunteers
Thrombosis
Biomarkers
Activins
Hepatitis C Antibodies
Survival
gamma-Glutamyltransferase
Transforming Growth Factor beta
Liver Diseases
Glycoproteins
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Confidence Intervals

Keywords

  • Follistatin
  • HCC
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. / Tomoda, Takeshi; Nouso, Kazuhiro; Miyahara, Koji; Kobayashi, Sayo; Kunugasa, Hideaki; Toyosawa, Junki; Hagihara, Hiroaki; Kuwaki, Kenji; Ohnishi, Hideki; Nakamura, Shinichiro; Ikeda, Fusao; Miyake, Yasuhiro; Shiraha, Hidenori; Takaki, Akinobu; Yamamoto, Kazuhide.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 28, No. 8, 2013, p. 1391-1396.

Research output: Contribution to journalArticle

Tomoda, T, Nouso, K, Miyahara, K, Kobayashi, S, Kunugasa, H, Toyosawa, J, Hagihara, H, Kuwaki, K, Ohnishi, H, Nakamura, S, Ikeda, F, Miyake, Y, Shiraha, H, Takaki, A & Yamamoto, K 2013, 'Prognotic impact of serum follistatin in patients with hepatocellular carcinoma', Journal of Gastroenterology and Hepatology (Australia), vol. 28, no. 8, pp. 1391-1396. https://doi.org/10.1111/jgh.12167
Tomoda, Takeshi ; Nouso, Kazuhiro ; Miyahara, Koji ; Kobayashi, Sayo ; Kunugasa, Hideaki ; Toyosawa, Junki ; Hagihara, Hiroaki ; Kuwaki, Kenji ; Ohnishi, Hideki ; Nakamura, Shinichiro ; Ikeda, Fusao ; Miyake, Yasuhiro ; Shiraha, Hidenori ; Takaki, Akinobu ; Yamamoto, Kazuhide. / Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. In: Journal of Gastroenterology and Hepatology (Australia). 2013 ; Vol. 28, No. 8. pp. 1391-1396.
@article{717307c68c604f6da07dafb382a37119,
title = "Prognotic impact of serum follistatin in patients with hepatocellular carcinoma",
abstract = "Background and Aim: Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. Methods: Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. Results: Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P=0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio=2.41, 95{\%} confidence interval=1.16-5.00, P=0.02). Conclusions: Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.",
keywords = "Follistatin, HCC, Prognosis",
author = "Takeshi Tomoda and Kazuhiro Nouso and Koji Miyahara and Sayo Kobayashi and Hideaki Kunugasa and Junki Toyosawa and Hiroaki Hagihara and Kenji Kuwaki and Hideki Ohnishi and Shinichiro Nakamura and Fusao Ikeda and Yasuhiro Miyake and Hidenori Shiraha and Akinobu Takaki and Kazuhide Yamamoto",
year = "2013",
doi = "10.1111/jgh.12167",
language = "English",
volume = "28",
pages = "1391--1396",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

AU - Tomoda, Takeshi

AU - Nouso, Kazuhiro

AU - Miyahara, Koji

AU - Kobayashi, Sayo

AU - Kunugasa, Hideaki

AU - Toyosawa, Junki

AU - Hagihara, Hiroaki

AU - Kuwaki, Kenji

AU - Ohnishi, Hideki

AU - Nakamura, Shinichiro

AU - Ikeda, Fusao

AU - Miyake, Yasuhiro

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Yamamoto, Kazuhide

PY - 2013

Y1 - 2013

N2 - Background and Aim: Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. Methods: Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. Results: Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P=0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio=2.41, 95% confidence interval=1.16-5.00, P=0.02). Conclusions: Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.

AB - Background and Aim: Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. Methods: Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. Results: Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P=0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio=2.41, 95% confidence interval=1.16-5.00, P=0.02). Conclusions: Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.

KW - Follistatin

KW - HCC

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84880651112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880651112&partnerID=8YFLogxK

U2 - 10.1111/jgh.12167

DO - 10.1111/jgh.12167

M3 - Article

C2 - 23432377

AN - SCOPUS:84880651112

VL - 28

SP - 1391

EP - 1396

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 8

ER -